Strata Skin Sciences (NASDAQ: SSKN) and Invuity (NASDAQ:IVTY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitabiliy, risk, analyst recommendations and dividends.
Earnings and Valuation
This table compares Strata Skin Sciences and Invuity’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Strata Skin Sciences | $31.41 million | 0.15 | $4.08 million | ($3.33) | -0.59 |
| Invuity | $35.08 million | 3.92 | -$35.41 million | ($2.66) | -3.05 |
Strata Skin Sciences has higher revenue, but lower earnings than Invuity. Invuity is trading at a lower price-to-earnings ratio than Strata Skin Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Strata Skin Sciences and Invuity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Strata Skin Sciences | -13.13% | -26.42% | -9.19% |
| Invuity | -118.92% | -129.81% | -68.06% |
Analyst Ratings
This is a breakdown of recent recommendations for Strata Skin Sciences and Invuity, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Strata Skin Sciences | 0 | 0 | 1 | 0 | 3.00 |
| Invuity | 0 | 0 | 5 | 0 | 3.00 |
Strata Skin Sciences currently has a consensus price target of $12.00, indicating a potential upside of 515.38%. Invuity has a consensus price target of $16.50, indicating a potential upside of 103.70%. Given Strata Skin Sciences’ higher possible upside, equities research analysts clearly believe Strata Skin Sciences is more favorable than Invuity.
Risk & Volatility
Strata Skin Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Invuity has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.
Insider & Institutional Ownership
96.2% of Strata Skin Sciences shares are held by institutional investors. Comparatively, 69.4% of Invuity shares are held by institutional investors. 14.5% of Strata Skin Sciences shares are held by company insiders. Comparatively, 10.5% of Invuity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Strata Skin Sciences beats Invuity on 8 of the 12 factors compared between the two stocks.
About Strata Skin Sciences
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.
Receive News & Ratings for Strata Skin Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strata Skin Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
